Official Public Statement from Alluvi Labs
Clarification Regarding Recent News Coverage
and Misrepresentation of Research Peptides
1. Context and Introduction
Alluvi acknowledges the recent Channel 4 News feature discussing research compounds and social-media sales. While the report mentioned Alluvi by name, it failed to reflect the facts of our operations and appeared to form part of a broader industry narrative driven by pharmaceutical commercial interests rather than public education. This statement clarifies Alluvi’s legal status, research focus, and regulatory compliance while responding to misleading or incomplete claims made in the programme.
2. The Nature of the Broadcast
Contrary to the presentation of an “independent investigation,” the programme reflected a coordinated communication effort supported by commercial competitors. Eli Lilly & Co., the manufacturer of Mounjaro (Tirzepatide), currently sells the same class of peptide for pharmaceutical use in the United States for more than $1,000 per pen and has lobbied for higher UK retail pricing. Following pricing restrictions in the UK and EU, Lilly has publicly signalled a reduction in supply to these markets recently.
The purpose of the broadcast therefore appears less about consumer protection and more about preserving market exclusivity for a multinational pharmaceutical brand. Alluvi operates as a Research and Development lab in proteins and amino acids independently and transparently to develop research-grade generic analogues for laboratory study only NOT pharmaceutical—an activity permitted under UK and EU R&D law and unrelated to pharmaceutical retail.
3. Regulatory Status – Lawful R&D Operations
Alluvi is a registered research and development company operating under:
- Companies Act 2006
- Health and Safety at Work Act 1974 and COSHH Regulations 2002 – chemical safety in laboratories
- REACH Regulation (EC 1907/2006) and CLP Regulation (EC 1272/2008) – classification and labelling
- General Product Safety Regulations 2005 – non-hazardous packaging
Exemption for research compounds. All products carry the statement: “For laboratory research and development purposes only. Not for human or veterinary use.”
This language aligns with MHRA guidance and EU Directive 2001/83/EC (Article 2) distinguishing research materials from medicines.
4. Misrepresentation by Third Parties
Some online sellers have misused the Alluvi name or branding without consent. Such behaviour constitutes passing off (Reckitt & Colman v Borden [1990] 1 WLR 491) and breaches the Consumer Protection from Unfair Trading Regulations 2008. Alluvi has filed formal removal notices and continues to monitor compliance.
Official domains:
www.ukalluvi.com
5. About Research Peptides and Generic Compounds
Peptides such as Retatrutide are chains of amino acids, long used in laboratory research contexts. These are not counterfeit medicines as defined by Human Medicines Regulations 2012 (Reg 269), because Alluvi does not imitate authorised brands nor make therapeutic claims. Independent laboratory testing confirms accurate composition and purity.
The regulatory distinction was recognised in MHRA v Peptide Clinics UK (2018), which held that “research-only” products without clinical claims fall outside the definition of a medicinal product.
6. Commercial Context and Public Misunderstanding
It is crucial to note that Eli Lilly did not invent the Retatrutide peptide; it has existed in open biochemical literature for over a decade. Early experimental use was observed among researchers studying biochemical pathways. Alluvi’s research-grade formulations simply make access to these peptides affordable for legitimate laboratory use.
The media narrative portraying all independent R&D suppliers as “illegal sellers” ignores the underlying scientific community that relies on affordable generics for study and development. Suppressing such access risks entrenches monopolies and slows innovation.
7. Consumer Safety and Ethical Standards
Alluvi operates under internal SOPs reflecting Good Laboratory Practice (GLP) and ISO 9001:2015 quality standards.
- Batch traceability and documentation
- Cold-chain handling (2–8 °C)
- Non-hazardous packaging per ADR 2019
- Prominent R&D-only disclaimers
Consumers are strongly advised not to purchase injectable products via social media or unverified resellers. Alluvi distributes solely through its official domains for institutional and analytical use.
8. Responsible Reporting and Transparency
Media scrutiny of the health sector is vital, but it must be factual. Equating compliant R&D suppliers with unlicensed drug dealers misleads the public and breaches the Defamation Act 2013 (S. 4), which protects opinion only when it is based on verifiable facts. Mischaracterizing a registered R&D company could constitute defamation or negligent misstatement (Byrne v Deane [1937] 1 KB 818).
9. Social Impact and Real-World Results
While Alluvi makes no therapeutic claims, it acknowledges the ongoing global interest in biochemical research. Thousands of laboratories have utilized peptide-based research materials globally, reinforcing the value of continued scientific exploration. The broader scientific issue is not research peptides themselves but misinformation and uncontrolled distribution outside legitimate laboratory channels.
10. Summary of Alluvi:
- Operates lawfully under UK/EU R&D frameworks.
- Has no social-media sales presence.
- Supplies research-grade peptides only, fully labeled and traceable.
- Reports fraudulent impersonators and misinformation.
We remain fully committed to ethical science, compliance, transparency, and consumer protection.
Contact Us
For any related queries, please contact:
AES Equipment Services LTD
Website: www.ukalluvi.com
